Search Results 1621-1630 of 19447 for hemoglobin

1. A Study To Investigate The Efficacy, Safety, And Pharmacokinetics Of Oral Rilzabrutinib Compared With Placebo In Participants 18 Years Of Age And Older With Warm Autoimmune Hemolytic Anemia - Mayo Clinic

   * Participants who have previously failed to maintain a sustained response after treatment with CS (CS-resistance \[defined as failure to obtain hemoglobin ...

2. A Study to Evaluate Estrogen Receptor (ER) Reactivation Therapy for Breast Cancer - Mayo Clinic

   Participation eligibility · hemoglobin > 9 g/dL; · white blood cell (WBC) count (≥ 2,000/uL); · platelet count ≥ 75,000/uL.

3. A Study Evaluating MM-310 in Patients With Solid Tumors - Mayo Clinic

   Hemoglobin > 9 g/dL. Patients must have adequate coagulation function as evidenced by prothrombin time (PT), activated partial thromboplastin time (aPTT) and ...

4. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Hemoglobin level ≤ 7.5 g/dL (≤5 mmol/L) (it is not permissible to transfuse a subject to reach this level);; Platelet count < 75 × 109/L for subjects in ...

5. Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer - Mayo Clinic

   hemoglobin must be greater than or equal to 10 g/dL. The following criteria for evidence of adequate hepatic function must be met based on the results of ...

6. Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery - Mayo Clinic

   Hemoglobin ≥ 9.0 gm/dL; Calculated creatinine clearance must be ≥ 45 ml/min using the Cockcroft-Gault formula; Eastern Cooperative Oncology Group (ECOG) ...

7. A Study of Grapiprant and Pembrolizumab in Patients with Advanced or Progressive MSS Colorectal Cancer - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L;; Note: Criteria must be met without erythropoietin dependency and without packed red blood cell transfusion within ...

8. Mayo Clinic study sheds light on rare genetic disorder and blood cancers

   Telomeres shorten naturally with age but become abnormally shorter in telomere biology disorders. People with these disorders often have bone marrow failure and ...

9. Novel HSF1 Pathway Inhibitor NXP800 In Patients with Advanced Cholangiocarcinoma - Mayo Clinic

   * Hemoglobin ≥ 9.0 g/dL (obtained ≤ 14 days prior to registration) * Absolute neutrophil count (ANC) ≥ 1500/mm\^3 (obtained ≤ 14 days prior to ...

10. A Phase 1 Study Of The Safety And Tolerability Of MT-125 In GBM Patients - Mayo Clinic

    Hemoglobin ≥9.0 g/dL 2. Absolute neutrophil count (ANC) ≥1500/mm3 3. Platelet count ≥100,000/mm3 4. Total bilirubin ≤1.5 x upper limit of normal (ULN) 5 ...